Dr. Xing Wu
Research ScientistUniversity of Basel, Basel, Switzerland
Highest Degree
Ph.D. in Biochemistry from University of Basel, Switzerland
Share this Profile
Area of Interest:
Selected Publications
- Hasinoff, B.B., X. Wu, D. Patel, R. Kanagasabai, S. Karmahapatra and J.C. Yalowich, 2016. Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisomerase IIα isoform. J. Pharmacol. Exp. Therapeut., 356: 397-409.
CrossRef | Direct Link | - Hasinoff, B.B., X. Wu, A.A. Yadav, D. Patel and H. Zhang et al., 2015. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochem. Pharmacol., 93: 266-276.
CrossRef | Direct Link | - Hasinoff, B.B., X. Wu, J.L. Nitiss, R. Kanagasabai and J.C. Yalowich, 2012. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem. Pharmacol., 84: 1617-1626.
CrossRef | Direct Link | - Wu, X., J.C. Yalowich and B.B. Hasinoff, 2011. Cadmium is a catalytic inhibitor of DNA topoisomerase II. J. Inorg. Biochem., 105: 833-838.
CrossRef | Direct Link | - Wu, X., H. Liang, K.A. O’Hara, J.C. Yalowich and B.B. Hasinoff, 2008. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase IIα. Chem. Res. Toxicol., 21: 483-493.
CrossRef | Direct Link | - Hasinoff, B.B., X. Wu, J.C. Yalowich, V. Goodfellow, R.S. Laufer, O. Adedayo and G.I. Dmitrienko, 2006. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: Antiproliferative and cell cycle effects. Anti-Cancer Drugs, 17: 825-837.
CrossRef | Direct Link | - Hasinoff, B.B., X. Wu, A. Begleiter, L.J. Guziec and F. Guziec et al., 2006. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother. Pharmacol., 57: 221-233.
CrossRef | Direct Link | - Wu, X. and B.B. Hasinoff, 2005. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anti-Cancer Drugs, 16: 93-99.
Direct Link | - Hasinoff, B.B., X. Wu, O.V. Krokhin, W. Ens and K.G. Standing et al., 2005. Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol. Pharmacol., 67: 937-947.
CrossRef | Direct Link | - Wu, X., D. Patel and B.B. Hasinoff, 2004. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. J. Inorg. Biochem., 98: 1818-1823.
CrossRef | Direct Link | - Hasinoff, B.B., X. Wu and Y. Yang, 2004. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl2(dexrazoxane) and cis-PtCl2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J. Inorg. Biochem., 98: 616-624.
CrossRef | Direct Link | - Wu, X. and H. Lee, 2002. Human Dbf4/ASK promoter is activated through the Sp1 and MluI cell-cycle box (MCB) transcription elements. Oncogene, 21: 7786-7796.
CrossRef | Direct Link |